These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37741017)

  • 21. Elevated plasma fibrinogen level shows superior prognostic value than Epstein-Barr virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.
    Lan M; Chen C; Huang Y; Mao M; Han F; Liao J; Deng M; Duan Z; Zheng L; Wu S; Lu T; Jian Y
    Oncotarget; 2016 Jul; 7(29):46242-46252. PubMed ID: 27323828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.
    Lee VH; Kwong DL; Leung TW; Choi CW; Lai V; Ng L; Lam KO; Ng SC; Sze CK; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; Khong PL
    Oncotarget; 2017 Jan; 8(3):5292-5308. PubMed ID: 28029657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating Epstein-Barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
    Shen EY; Hung TM; Tsan DL; Cheng NM; Kang CJ; Huang SF; Hsu CL; Lin CY; Wang HM; Hsieh JC; Cheng AJ; Fan KH; Chang JT
    Radiother Oncol; 2022 Dec; 177():1-8. PubMed ID: 35568282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study.
    Lv JW; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Guo R; Lin AH; Ma J; Sun Y
    Oncotarget; 2016 Mar; 7(13):16806-17. PubMed ID: 26919237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.
    Wu YL; Yang KB; Huang Y; Shi JR; He QS; Chen L; Li WF; Huang XD; Lin L; Chen YP; Mao YP; Tang LL; Ma J
    Radiat Oncol; 2022 Aug; 17(1):138. PubMed ID: 35941674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
    Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
    Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.
    Fei Z; Xu T; Qiu X; Li M; Chen T; Li L; Huang C; Chen C
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2047-2055. PubMed ID: 33392660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.
    Kong FF; Pan GS; Du CR; Ni MS; Zhai RP; He XY; Shen CY; Lu XG; Hu CS; Ying HM
    Radiother Oncol; 2023 Aug; 185():109721. PubMed ID: 37244356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.
    Yuan X; Yang H; Zeng F; Zhou S; Wu S; Yuan Y; Cui L; Feng H; Lin D; Chen Z; Liu X; Chen J; Wang F
    BMC Cancer; 2022 Aug; 22(1):858. PubMed ID: 35932022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy.
    Ji P; Lu Q; Chen X; Chen Y; Peng X; Chen Z; Lin C; Lin S; Zong J
    Cancer Res Treat; 2023 Oct; 55(4):1113-1122. PubMed ID: 37170497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
    Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
    Yang K; Tian J; Zhang B; Li M; Xie W; Zou Y; Tan Q; Liu L; Zhu J; Shou A; Li G
    Oral Oncol; 2019 Nov; 98():85-91. PubMed ID: 31569054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.
    Peng H; Chen L; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    PLoS One; 2016; 11(11):e0166194. PubMed ID: 27835689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma.
    Lu L; Li J; Zhao C; Xue W; Han F; Tao T; Chang H; Jia W; Lu T
    Oral Oncol; 2016 Sep; 60():18-24. PubMed ID: 27531868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma.
    Chen WH; Tang LQ; Zhang L; Chen QY; Guo SS; Liu LT; Fan W; Zhang X; Guo L; Zhao C; Cao KJ; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Oncotarget; 2015 Nov; 6(35):38296-307. PubMed ID: 26512922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
    Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
    Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
    Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
    Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
    Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
    BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.